Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

5(62.5%)

Phase 4

1(12.5%)

N/A

1(12.5%)

Phase 1

1(12.5%)

8Total

Phase 2(5)

Phase 4(1)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07421141Phase 2Active Not Recruiting

De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer

Role: lead

NCT07400094Phase 2Not Yet Recruiting

Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC

Role: lead

NCT07401498Not ApplicableEnrolling By Invitation

Complications Associated With Lymphadenectomy (LAD) in Surgical Treatment of Non-small Cell Lung Cancer (NSCLC).

Role: collaborator

NCT06984146Phase 2Recruiting

Nivo40-AVD for Advanced Classic Hodgkin Lymphoma

Role: lead

NCT06277921Completed

Morbidity and Mortality After Esophageal and Esophagogastric Junction Cancer Surgery

Role: collaborator

NCT06856603Phase 2Recruiting

OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites

Role: lead

NCT06556550Phase 2Recruiting

Stereotactic Radiotherapy for Oligometastasis (1-5) in Various Tumor Sites vs. Palliative Care

Role: lead

NCT06277908Not Yet Recruiting

Postoperative Morbidity and Mortality After Gastric Cancer Surgery

Role: collaborator

NCT05046028Phase 4Completed

Individualization of Nutritive Sensory Support Of Radiation Therapy

Role: lead

NCT04724538Phase 1Completed

Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19

Role: lead

All 10 trials loaded